How do you view epcoritamab + R² in an older or frail patient with follicular lymphoma who would otherwise be a candidate for additional treatment after progresion on first line therapy?

It really depends on the fitness of an older patient or the specific comorbidities of a frail patient, along with what their initial treatment was, when they received initial therapy, and what is driving the need for treatment. However, this is a more intense schedule for the first 3 cycles with wee...

Older and frail patients often derive less benefit from repeated chemotherapy as cumulative toxicity becomes increasingly important. ER2 offers the potential for a highly effective chemotherapy-free approach while maintaining an acceptable safety profile, but I think careful patient selection is ess...